SI9200297B - Antagonisti endotelinskih receptorjev - Google Patents

Antagonisti endotelinskih receptorjev Download PDF

Info

Publication number
SI9200297B
SI9200297B SI9200297A SI9200297A SI9200297B SI 9200297 B SI9200297 B SI 9200297B SI 9200297 A SI9200297 A SI 9200297A SI 9200297 A SI9200297 A SI 9200297A SI 9200297 B SI9200297 B SI 9200297B
Authority
SI
Slovenia
Prior art keywords
hydrogen
alkyl
methylenedioxyphenyl
methoxyphenyl
formula
Prior art date
Application number
SI9200297A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9200297A (en
Inventor
Donovan Russell Cousins
Duncah John Elliott
Amparo Maria Lago
Dale Jack Leber
Elizabeth Catherine Peishoff
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SI9200297A publication Critical patent/SI9200297A/sl
Publication of SI9200297B publication Critical patent/SI9200297B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9200297A 1991-11-05 1992-11-03 Antagonisti endotelinskih receptorjev SI9200297B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78787091A 1991-11-05 1991-11-05
US85419592A 1992-03-20 1992-03-20

Publications (2)

Publication Number Publication Date
SI9200297A SI9200297A (en) 1993-06-30
SI9200297B true SI9200297B (sl) 2003-02-28

Family

ID=27120702

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9200297A SI9200297B (sl) 1991-11-05 1992-11-03 Antagonisti endotelinskih receptorjev

Country Status (33)

Country Link
EP (1) EP0612244B1 (fi)
JP (1) JP2667294B2 (fi)
KR (1) KR100342960B1 (fi)
CN (2) CN1034569C (fi)
AP (1) AP433A (fi)
AT (1) ATE205711T1 (fi)
AU (1) AU669866B2 (fi)
BG (1) BG61523B1 (fi)
BR (1) BR9206722A (fi)
CA (1) CA2122820A1 (fi)
CZ (1) CZ287406B6 (fi)
DE (1) DE69232072T2 (fi)
DK (1) DK0612244T3 (fi)
ES (1) ES2164054T3 (fi)
FI (1) FI942059A (fi)
HK (1) HK1012251A1 (fi)
HU (1) HUT67665A (fi)
IL (1) IL103621A0 (fi)
MA (1) MA22758A1 (fi)
MX (1) MX9206348A (fi)
MY (1) MY108579A (fi)
NO (1) NO304887B1 (fi)
NZ (1) NZ245000A (fi)
OA (1) OA09921A (fi)
PL (1) PL176250B1 (fi)
PT (1) PT101038B (fi)
RO (1) RO117847B1 (fi)
RU (1) RU2125980C1 (fi)
SI (1) SI9200297B (fi)
SK (1) SK282098B6 (fi)
TW (1) TW298590B (fi)
UA (1) UA44686C2 (fi)
WO (1) WO1993008799A1 (fi)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5817693A (en) 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO1993023404A1 (en) * 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
ES2062927B1 (es) * 1992-12-17 1995-07-01 Smithkline Beecham Corp Antagonistas de los receptores de endotelina y procedimiento para su preparacion.
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
GB9307694D0 (en) 1993-04-14 1993-06-02 Smithkine Beecham Corp Novel compounds
CA2121724A1 (en) * 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
DZ1773A1 (fr) * 1993-04-27 2002-02-17 Smithkline Beecham Corp Antagonistes de récepteurs d'endothéline.
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
EP0711157A4 (en) * 1993-08-06 1996-07-31 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
EP0723449A1 (en) * 1993-08-06 1996-07-31 Smithkline Beecham Corporation Endothelin receptor antagonists
ATE199151T1 (de) * 1993-08-18 2001-02-15 Banyu Pharma Co Ltd Kondensierte heteroaromatische cyclopentenderivate mit endothelin- antagonistischer aktivität
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5714479A (en) * 1993-08-18 1998-02-03 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
WO1997007119A1 (en) * 1994-08-26 1997-02-27 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
AU691201B2 (en) * 1993-11-01 1998-05-14 Japat Ltd. Endothelin receptor antagonists
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
WO1995033748A1 (en) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH10501812A (ja) * 1994-06-20 1998-02-17 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗薬
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
ATE219077T1 (de) * 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
WO1996020193A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
ATE186054T1 (de) * 1995-06-30 1999-11-15 Cerbios Pharma Sa Glykoside, deren zuckerfreie abbauprodukte und derivate derselben
DE19527568A1 (de) * 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
ZA969363B (en) 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
CA2236924A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
CO4761056A1 (es) * 1995-11-08 1999-04-27 Smithkline Beecham Corp Procedimiento para preparar derivados de ciclopentano condensados con anillos aromaticos
AU1054297A (en) * 1995-11-08 1997-05-29 Smithkline Beecham Corporation A process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
DE19543639A1 (de) * 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
CA2245587C (en) * 1996-02-13 2008-12-30 Abbott Laboratories Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
HUP9902316A3 (en) * 1996-02-13 2001-12-28 Abbott Lab 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing them
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
CN1211183A (zh) 1996-02-20 1999-03-17 布里斯托尔-迈尔斯斯奎布公司 联苯基异噁唑磺酰胺的制备方法
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
ES2179353T3 (es) * 1996-07-01 2003-01-16 Schering Corp Antagonistas muscarinicos.
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US6172235B1 (en) 1996-08-09 2001-01-09 Merck & Co., Inc. Asymmetric conjugate addition reaction
ATE251611T1 (de) * 1996-08-09 2003-10-15 Merck & Co Inc Additionsreaktion mit asymmetrischem konjugat
CA2262676A1 (en) * 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
AU3867997A (en) 1996-08-27 1998-03-19 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
HRP980001A2 (en) * 1997-01-14 1998-10-31 Feng Xu Asymmetric conjugate addition reaction using a chiral additive
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6013674A (en) * 1997-06-02 2000-01-11 Eli Lilly And Company Cell adhesion inhibitors
JP4058507B2 (ja) 1997-07-10 2008-03-12 国立大学法人 東京医科歯科大学 ４，５−ジヒドロ−［１Ｈ］−ベンズ［ｇ］インダゾール−３−カルボン酸誘導体
US6022972A (en) 1997-08-08 2000-02-08 Merck & Co., Inc. Pyridine propanoic acid derivatives
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
AU742423B2 (en) * 1998-01-21 2002-01-03 Msd K.K. Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
KR20020004974A (ko) 1999-03-19 2002-01-16 스티븐 비. 데이비스 비페닐 이속사졸 술폰아미드의 제조방법
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
ATE272048T1 (de) * 1999-05-26 2004-08-15 Warner Lambert Co Aminosäuren mit polycyclischer struktur als pharmaka
MXPA02000242A (es) 1999-06-30 2004-09-10 Prescient Neuropharma Inc Analogos de 2-aminoindano.
ES2236028T3 (es) 1999-12-31 2005-07-16 Encysive Pharmaceuticals, Inc Sulfonamidas y sus derivados que modulan la actividad de la endotelina.
KR101009472B1 (ko) 2001-06-12 2011-01-19 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
KR100595963B1 (ko) * 2004-04-13 2006-07-05 한국화학연구원 인덴 유도체 및 이의 제조방법
RU2388748C2 (ru) 2004-12-21 2010-05-10 Ф. Хоффманн-Ля Рош Аг Производные тетралина и индана и их применения в качестве антагонистов 5-нт
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
EP3000487B8 (en) 2007-02-19 2022-06-15 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
JP2013523898A (ja) 2010-04-15 2013-06-17 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバーの抗菌性の適用
EP2696680B1 (en) 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
CN110343038B (zh) * 2018-04-02 2022-03-15 暨南大学 一种宝乐果单体、提取物及其制备方法和应用
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical preparations that modulate IKZF2
WO2024005578A1 (ko) * 2022-06-29 2024-01-04 아밀로이드솔루션 주식회사 신규 인덴온 유도체 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642785A (en) * 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
US4224341A (en) * 1976-01-12 1980-09-23 Lipha, Lyonnaise Industrielle Pharmaceutique 5-Substituted indan-2 carboxylic acid and functional derivatives
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
JPS61197557A (ja) * 1985-02-27 1986-09-01 Sankyo Co Ltd インダン誘導体およびその製法
IT1190371B (it) * 1985-06-19 1988-02-16 Zambon Spa Processo per la preparazione dell'acido cis-5-fluoro-2-metil-1-(4-metiltiobenziliden)-indenil-3-acetico

Also Published As

Publication number Publication date
CZ110994A3 (en) 1995-01-18
CA2122820A1 (en) 1993-05-13
CZ287406B6 (cs) 2000-11-15
AP9200440A0 (en) 1993-01-31
PT101038B (pt) 1999-07-30
SK282098B6 (sk) 2001-11-06
HK1012251A1 (en) 1999-07-30
PL176250B1 (pl) 1999-05-31
AU3125993A (en) 1993-06-07
MY108579A (en) 1996-10-31
CN1073161A (zh) 1993-06-16
BG98752A (bg) 1995-05-31
CN1145223A (zh) 1997-03-19
NO304887B1 (no) 1999-03-01
FI942059A (fi) 1994-07-04
OA09921A (en) 1994-08-15
PT101038A (pt) 1994-02-28
KR100342960B1 (fi) 2003-02-11
ATE205711T1 (de) 2001-10-15
DE69232072T2 (de) 2002-06-20
HU9401319D0 (en) 1994-08-29
AP433A (en) 1995-11-17
WO1993008799A1 (en) 1993-05-13
JPH07501322A (ja) 1995-02-09
EP0612244A4 (en) 1995-05-17
JP2667294B2 (ja) 1997-10-27
MX9206348A (es) 1994-06-30
SI9200297A (en) 1993-06-30
NO941650D0 (no) 1994-05-04
SK52194A3 (en) 1995-03-08
UA44686C2 (uk) 2002-03-15
NO941650L (no) 1994-07-01
DE69232072D1 (de) 2001-10-25
CN1034569C (zh) 1997-04-16
HUT67665A (en) 1995-04-28
NZ245000A (en) 1996-05-28
TW298590B (fi) 1997-02-21
AU669866B2 (en) 1996-06-27
BR9206722A (pt) 1995-07-18
IL103621A0 (en) 1993-04-04
BG61523B1 (en) 1997-11-28
EP0612244B1 (en) 2001-09-19
ES2164054T3 (es) 2002-02-16
EP0612244A1 (en) 1994-08-31
RU2125980C1 (ru) 1999-02-10
FI942059A0 (fi) 1994-05-04
MA22758A1 (fr) 1993-10-01
DK0612244T3 (da) 2002-01-14
RO117847B1 (ro) 2002-08-30

Similar Documents

Publication Publication Date Title
SI9200297B (sl) Antagonisti endotelinskih receptorjev
SI9400195B (sl) Antagonisti endotelinskih receptorjev
RU95122388A (ru) Антагонисты эндотелинового рецептора
CA2040955A1 (en) Benzimidazole derivatives, their production and use
AR044981A1 (es) Combinacion de un inhibidor alosterico de metaloproteinasa de matriz 13 (mmp-13) y un ligando de un receptor alfa-2- delta
RU99109576A (ru) Амины аминотиофенкарбоновой кислоты и их применение
RU97106022A (ru) Лиганды x-рецептора ретиноевой кислоты
FR2800375B1 (fr) Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
RU99119223A (ru) Бициклические автоматические аминокислоты
DE69032414D1 (de) Diphenylmethane derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
EP1413576A3 (en) Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
ES2101824T3 (es) N-acil-n-heterociclil-onaftalenil-alquil-aminoacidos como antagonistas de angiotensina ii.
EA200200952A1 (ru) Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
SK391292A3 (en) 4-alkyimidazole derivatives
EP0309422A3 (en) New amidino tricycle derivatives
ATE320424T1 (de) Verfahren zu herstellung von citalopram
RU2001114188A (ru) Производные хроменона и хроманона в качестве ингибиторов интегринов
NO943231L (no) Aromatiske karboksylsyrederivater
BR9917205A (pt) Antagonistas de retinóides e seu uso
EP0351385A3 (en) New amidino and guanidino derivatives
DK0542554T3 (da) Substituerede N-biphenylyllactamer
RU2003131971A (ru) Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств
FR2527206A1 (fr) Nouveaux derives de la 2(1h)-pyridinone, leur preparation et leur utilisation comme medicaments
MX9207204A (es) Preparado farmaceutico y procedimiento para su fabricacion.

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20100611